VISIT BOOTH 36157 2024 ASCO® Annual Meeting
This site is intended for US healthcare professionals
See 3-YEAR follow-up data1

Efficacy

hero imagehero image

Primary analysis

Primary endpoint: median overall survival

Largest phase 3 trial in metastatic uveal melanoma (mUM) evaluated first-line treatment with KIMMTRAK vs investigator’s choice (IC)1,2

  • Investigator’s choice included checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine)1,2
See more study design details

First-line treatment with KIMMTRAK significantly extended median overall survival (mOS) by 6 months vs IC1,2

Chart
Chart
≈50% reduction in the risk of death1,2
At the time of the data cutoff for the first interim analysis, median duration of follow-up was 14.1 months.2

3-YEAR follow-up analysis

Overall survival at 3-YEAR follow-up analysis

27.4% of patients were ALIVE AT 3 YEARS WITH KIMMTRAK vs 17.8% with investigator’s choice3,*

A graph that shows KIMMTRAK efficacy data and its impact on mUM over a 69-month period vs the investigator's choice
Pinch to zoom

No new safety signals were identified at the 3-YEAR follow-up analysis.3

Median duration of follow-up: 43.3 months (minimum follow-up: 36 months).3 The mOS was 21.6 months (95% CI, 19.0-24.3) in the KIMMTRAK group vs 16.9 months (95% CI, 12.9-19.5) in the investigator’s choice group.3

The planned exploratory 3-YEAR overall survival analysis occurred after the protocol-specified final analysis and was not tested for statistical significance. No statistical conclusions can be drawn.

CI, confidence interval; HR, hazard ratio.

  • * Investigator’s choice: checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine).3

Pivotal trial

Select secondary endpoints

  • Progression-free survival (PFS) and objective response rate (ORR) were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 11,2
  • A statistically significant PFS benefit was seen with KIMMTRAK compared to investigator’s choice* (3.3 months vs 2.9 months respectively, HR = 0.73; 95% CI, 0.58-0.94; P = 0.0139)1,2

At the time of the data cutoff for this first interim analysis, median duration of follow-up was 14.1 months.2

A graph that shows KIMMTRAK efficacy data surrounding ORR, DCR, and SD vs the investigator's choice

3-YEAR follow-up analysis

Time to objective response
2.9 months with KIMMTRAK (range, 1.2 to 22.2)
vs 4.1 months with IC* (range, 2.0 to 11.8).3

Median duration of response
11.1 months with KIMMTRAK
vs 9.7 months with IC.3,*

  • In the 3-YEAR follow-up analysis, only ORR (11%) and SD (35%) with KIMMTRAK changed3
  • * Investigator’s choice: checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine).1-3
  • aNot formally tested.1
  • bDCR was defined as a complete response (CR) + partial response (PR) + SD.2,4

3-YEAR follow-up analysis

Post hoc analysis of patients with a best overall response of progressive disease (PD) by day 100

100-day landmark analysis3
A graph that shows KIMMTRAK efficacy data surrounding mOS vs the investigator's choice over a 60-month period
Pinch to zoom

The post hoc overall survival among patients with best overall response of disease progression analysis by day 100 after randomization occurred after the protocol-specified final analysis and was not tested for statistical significance. These data are not included in the Prescribing Information. The statistical significance is not known and data should be interpreted with caution.

Treatment with KIMMTRAK should be continued while patient is deriving clinical benefit and in the absence of unacceptable toxicities.1

  • Over half (57%; n = 139) of patients who received KIMMTRAK were treated beyond initial radiographic progression vs 25% (n = 28) in the control group3
  • *Investigator’s choice: checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine).3

The largest phase 3 trial in mUM compared KIMMTRAK
with checkpoint inhibitors or chemotherapy in first-line
1,2

An international, multicenter, phase 3, pivotal, 2:1 randomized, controlled trial of 378 HLA-A*02:01-positive adult patients with mUM compared KIMMTRAK with investigator’s choice1,2,5

  • Investigator's choice included checkpoint inhibitors (pembrolizumab [82%], ipilimumab [12%]) or chemotherapy (dacarbazine [6%])2

Pivotal trial

Study design1,2,5

A flow chart that shows the stages of the KIMMTRAK phase 3 clinical trial process

Radiologic assessment every 12 weeks.

Primary end point1

  • Overall survival

Select secondary end points1,2,5

  • Adverse events5
  • Progression-free survival1
  • Objective response rate1
  • Duration of response5
  • Disease control rate2

Select enrollment criteria5

Inclusion

  • Histologically or cytologically confirmed mUM
  • No prior systemic therapy, including chemotherapy, immunotherapy, or targeted therapy, in the metastatic or advanced setting
  • No prior regional, liver-directed therapy, including chemotherapy, radiotherapy, or embolization
  • Prior surgical resection of oligometastatic disease was allowed
  • Prior neoadjuvant or adjuvant therapy was allowed, provided it was administered in the curative setting in patients with localized disease. Patients could not be re-treated with an investigator’s choice* therapy that was administered as adjuvant or neoadjuvant treatment. Additionally, patients who had received nivolumab as prior adjuvant/neoadjuvant treatment were not to receive pembrolizumab as investigator’s choice therapy
  • HLA-A*02:01 positive by central assay
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 at screening

HLA-A, human leukocyte antigen-A; LDH, lactate dehydrogenase; ULN, upper limit of normal.

  • *Investigator’s choice: checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine).5
Baseline characteristics
A graph that shows KIMMTRAK efficacy data surrounding baseline characteristics vs the investigator's choiceA graph that shows KIMMTRAK efficacy data surrounding baseline characteristics vs the investigator's choice
  • aOne patient had an ECOG PS of 2 (investigator’s choice); 20 patients had a missing ECOG status (11 KIMMTRAK, 9 investigator’s choice).
  • bThree patients had missing metastasis location (1 KIMMTRAK, 2 investigator’s choice).

Exclusion

  • History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
  • Clinically significant cardiac disease or impaired cardiac function
  • Presence of symptomatic or untreated central nervous system metastases
  • Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of study drug

HLA-A, human leukocyte antigen-A; LDH, lactate dehydrogenase; ULN, upper limit of normal.

  • *Investigator’s choice: checkpoint inhibitors (pembrolizumab and ipilimumab) or chemotherapy (dacarbazine).5
Baseline characteristics
A graph that shows KIMMTRAK efficacy data surrounding baseline characteristics vs the investigator's choice
  • aOne patient had an ECOG PS of 2 (investigator’s choice); 20 patients had a missing ECOG status (11 KIMMTRAK, 9 investigator’s choice).
  • bThree patients had missing metastasis location (1 KIMMTRAK, 2 investigator’s choice).
Indication
 
Important Safety Information Including Boxed Warning

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

WARNING: CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.

Indication and Important Safety Information Including Boxed Warning

Indication

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Important Safety Information Including Boxed Warning

WARNING: CYTOKINE RELEASE SYNDROME
Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.
Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin ReactionsSkin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal ToxicityKIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

Please see full Prescribing Information, including BOXED WARNING for CRS.

References:
1. Kimmtrak. Package insert. Immunocore Ltd; 2022. 2. Nathan P, Hassel JC, Rutkowski P, et al; IMCgp100-202 Investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196-1206. doi:10.1056/NEJMoa2103485 3. Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256-2266. doi:10.1056/NEJMoa2304753 4. Nathan P, Hassel JC, Rutkowski P, et al; IMCgp100-202 Investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13)(suppl):1196-1206. doi:10.1056/NEJMoa2103485 5. Safety and efficacy of IMCgp100 versus investigator choice in advanced uveal melanoma. ClinicalTrials.gov identifier: NCT03070392. Published March 3, 2017. Updated March 7, 2023. Accessed January 4, 2024.